The drug, developed at Duke University Medical Center, uses one type of genetic material, called targeting RNA, to enter cancer cells, and another type, called silencing RNA, to stop the expression of a protein that keeps the cells alive.
In tests in mice with prostate cancer, the drug shrank the size of their tumors by half, while the tumors in control mice that did not receive the drug continued to grow, said study co-author Bruce Sullenger, Ph.D., director of Duke's Translational Research Institute and chief of the Division of Experimental Surgery.
The mice showed no side effects from the treatment, Sullenger said.
"This study represents the first step in creating an RNA-based drug for cancer," said lead author James McNamara, Ph.D. a postdoctoral fellow in experimental surgery. "It provides a 'proof of principle' that an entirely RNA-based drug can work with minimal side effects, and it shows it is possible to overcome many of the obstacles that have hampered the development of RNA-based drugs."
The study is reported in the August 2006 issue of Nature Biotechnology, which is now available online. The research was funded by the National Institutes of Health.
Duke has filed a provisional patent application on the technology, according to the researchers.
"Scientists have made numerous attempts to transform silencing RNAs into natural anticancer agents, but such development has been challenging," said Paloma Giangrande, Ph.D., co-leader of the study and an assistant research professor in experimental surgery.
Scientists have encountered major obstacles when trying to deliver silencing RNAs to tumors, Giangrande said. Previous RNA-based drugs have been nonspecific, targeting all cells in the body and not just cancer cells. As a result, they have caused unwanted side effects.
The Duke team set out to produce a drug that would target only cancer cells. To accomplish this goal, the researchers designed a drug that combines two RNA "modules" that work in stages. One module contains targeting RNA, which attaches to a protein, PMSA, found only on the surface of prostate cancer cells. When that module binds to a cancer cell, the cell reacts by engulfing the entire drug molecule.
With the drug now inside the cancer cell, the second module, which contains silencing RNA, launches its effect. The silencing RNA seeks out and binds to the RNA for a specific cancer-causing protein, called PLK1, and tags it for destruction. This eventually leads to the death of the cancer cell.
The researchers first tested the drug in culture dishes containing cancer cells. They found that the drug effectively bound to prostate cancer cells, entered them and shut off production of the target protein, PLK1.
The researchers then moved into mouse experiments. They injected the drug directly into the mice's prostate tumors, administering one injection every two days, for a total of 10 injections over 20 days. By the end of the study, the tumors in the 10 treated mice had shrunk two-fold in volume, while the tumors in the 10 control animals had more than tripled in size.
"The animals themselves showed no signs of side effects," Giangrande said.
The scientists caution that much work remains to move the experimental drug into clinical use in humans. Among the next steps, Sullenger said, is to demonstrate conclusively that the drug can be delivered into the blood stream and still reach the tumor target without being destroyed by the body or causing adverse side effects.
Other Duke researchers involved in the study include Eran Andrechek, Yong Wang, Kristi Viles, Rachel Rempel and Eli Gilboa.
Marla Vacek Broadfoot | EurekAlert!
How brains surrender to sleep
23.06.2017 | IMP - Forschungsinstitut für Molekulare Pathologie GmbH
A new technique isolates neuronal activity during memory consolidation
22.06.2017 | Spanish National Research Council (CSIC)
An international team of scientists has proposed a new multi-disciplinary approach in which an array of new technologies will allow us to map biodiversity and the risks that wildlife is facing at the scale of whole landscapes. The findings are published in Nature Ecology and Evolution. This international research is led by the Kunming Institute of Zoology from China, University of East Anglia, University of Leicester and the Leibniz Institute for Zoo and Wildlife Research.
Using a combination of satellite and ground data, the team proposes that it is now possible to map biodiversity with an accuracy that has not been previously...
Heatwaves in the Arctic, longer periods of vegetation in Europe, severe floods in West Africa – starting in 2021, scientists want to explore the emissions of the greenhouse gas methane with the German-French satellite MERLIN. This is made possible by a new robust laser system of the Fraunhofer Institute for Laser Technology ILT in Aachen, which achieves unprecedented measurement accuracy.
Methane is primarily the result of the decomposition of organic matter. The gas has a 25 times greater warming potential than carbon dioxide, but is not as...
Hydrogen is regarded as the energy source of the future: It is produced with solar power and can be used to generate heat and electricity in fuel cells. Empa researchers have now succeeded in decoding the movement of hydrogen ions in crystals – a key step towards more efficient energy conversion in the hydrogen industry of tomorrow.
As charge carriers, electrons and ions play the leading role in electrochemical energy storage devices and converters such as batteries and fuel cells. Proton...
Scientists from the Excellence Cluster Universe at the Ludwig-Maximilians-Universität Munich have establised "Cosmowebportal", a unique data centre for cosmological simulations located at the Leibniz Supercomputing Centre (LRZ) of the Bavarian Academy of Sciences. The complete results of a series of large hydrodynamical cosmological simulations are available, with data volumes typically exceeding several hundred terabytes. Scientists worldwide can interactively explore these complex simulations via a web interface and directly access the results.
With current telescopes, scientists can observe our Universe’s galaxies and galaxy clusters and their distribution along an invisible cosmic web. From the...
Temperature measurements possible even on the smallest scale / Molecular ruby for use in material sciences, biology, and medicine
Chemists at Johannes Gutenberg University Mainz (JGU) in cooperation with researchers of the German Federal Institute for Materials Research and Testing (BAM)...
19.06.2017 | Event News
13.06.2017 | Event News
13.06.2017 | Event News
23.06.2017 | Physics and Astronomy
23.06.2017 | Physics and Astronomy
23.06.2017 | Information Technology